Polyamine Treatment in Elderly Patients With Coronary Artery Disease

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

PHASE2

Total Enrollment

180 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-01-01

Study Completion Date

2027-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The present study is testing spermidine treatment in elderly patients with coronary artery disease. The study is a randomized, double-blind, placebo-controlled, two-armed, parallel-group, single centre, clinical study.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effects of Nutraceutical Therapies on Endothelial Function, Platelet Aggregation, and Coronary Flow Reserve

NCT02969070

Hypercholesterolemia Endothelial Dysfunction

COMPLETED NA

Effect of Pyridoxamine Supplementation on Vascular Function and Insulin Sensitivity

NCT02954588

Abdominal Obesity Metabolic Syndrome

COMPLETED NA

Mediterranean Diet and Nutritional Support in Heart Failure Sarcopenia

NCT05848960

Sarcopenia

COMPLETED NA

Living With Statins - The Impact of Cholesterol Lowering Drugs on Health, Lifestyle and Well-being

NCT02255682

Cardiovascular Disease Diabetes Mellitus

COMPLETED PHASE4

The Role of a Combination of Nutraceuticals in the Control of Cardiovascular Risk

NCT01293162

Metabolic Syndrome

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Life expectancy has increased tremendously over the past century and as populations age, chronic diseases such as cardiovascular disease and diabetes have become more prevalent. Healthy aging is therefore of paramount importance to further promote longevity and quality of life.

In humans, a high concentration of whole-blood spermidine is associated with longevity, and individuals with a high dietary spermidine intake have improved cardiovascular health and less obesity. Spermidine is essentially a polyamine found in all plant-derived foods, particularly in whole grains, soybeans, nuts, and fruit. Its favorable effects may act via several mechanisms. In an experimental model of hypertensive heart disease, spermidine reduced cardiac hypertrophy and improved diastolic and mitochondrial function. Spermidine also induces cytoprotective autophagy in skeletal muscle and alters body fat accumulation by metabolically modulating glucose and lipid metabolism.

The clinical data on spermidine dietary supplementation are scarce. In elderly subjects with cognitive problems, spermidine supplement was well tolerated and had potential blood-pressure-lowering effects. The reported beneficial effects of spermidine raise the question whether elderly patients with cardiovascular disease can benefit from a dietary supplement of this polyamine.

The central hypothesis of the current proposal is that a twelve-month spermidine treatment regimen in elderly patients with cardiovascular disease will yield positive effects on heart and skeletal muscle function, whole body composition and inflammation. The secondary hypotheses are that spermidine reduces blood pressure and has a beneficial impact on cognitive function, daily activity level, quality of life, biomarker risk profile, skeletal muscle cellular metabolism and lastly but not least gut microbiota.

The study design is a randomized, double-blind, placebo-controlled trial to investigate the effects of a 24 mg daily oral spermidine dietary supplement vs. matching placebo in elderly patients with cardiovascular disease. A total of 200 patients will be included and randomized 1:1 to either spermidine 24 mg x 1 daily or matching placebo for one year.

At baseline and after one year of intervention the patients will undergo study procedures. Changes from baseline to follow-up will be compared between the active and placebo treated patient groups.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Ischemic Heart Disease Myocardial Infarction Cardiovascular Diseases Hypertensive Heart Disease Hypertension Diastolic Dysfunction Obesity Metabolic Syndrome Diabetes Mellitus, Type 2 Dietary Habits Inflammation Quality of Life Cognition Disorder Cognitive Impairment

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Randomized, double-blind, placebo-controlled, two-armed, parallel-group, single centre, clinical study.

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Double (Participant, Investigator)

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Spermidine

Spermidine will be given orally as capsules of cellulose with spermidine (24 mg/day) and rice flour.

Group Type ACTIVE_COMPARATOR

Spermidine

Intervention Type DIETARY_SUPPLEMENT

Spermidine capsule of 8 mg x 3 capsules daily.

Placebo

Placebo will be given orally as capsules of cellulose and rice flour (same size and visual appearance as spermidine capsules)

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type OTHER

Placebo capsule. 3 capsules daily.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Spermidine

Spermidine capsule of 8 mg x 3 capsules daily.

Intervention Type DIETARY_SUPPLEMENT

Placebo

Placebo capsule. 3 capsules daily.

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Polyamine

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age ≥ 65 years
* Chronic ischemic heart disease (previous revascularization or myocardial infarction)
* Left ventricular ejection fraction of \> 40%

And at least two of the following risk factors:

* Type 2 diabetes,
* Obesity (BMI ≥ 30 kg/m2),
* Hypertension,
* Previous LVEF \< 40%,
* Left atrial volume index ≥ 30 mL/m2
* Left ventricular wall thickness ≥ 1.1 cm.

Exclusion Criteria

* Unstable coronary syndrome
* Significant and severe cardiac valve disease
* Severe peripheral artery disease
* Permanent atrial fibrillation
* Pacemaker treatment
* Chronic kidney disease with eGFR \<45 ml/min/1,73m2
* Severe comorbidity as judged by the investigator (such as severe pulmonary, neurological, or musculoskeletal disease)
* Inability to give informed consent.

* Some metallic implants
* Claustrophobia

* Treatment with either two antiplatelet drugs (aspirin and ADP-receptor antagonists)
* Anticoagulants (warfarin, NOACs)

Minimum Eligible Age

65 Years

Maximum Eligible Age

90 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No